Evolus Expects Q4 EPS $0.06, Revenue $89.4M; Mizuho Cuts Target to $15
Evolus will report Q4 and full-year 2025 results on March 3 with consensus EPS of $0.06 (500% YoY) and projected revenues of $89.42 million (13.3% YoY). Mizuho cut its price target to $15 while maintaining an Outperform rating and Evolus plans to participate in the Leerink Partners Global Healthcare Conference.
1. Upcoming Q4 Results
Evolus is scheduled to release its fourth-quarter and full-year 2025 results on March 3. Consensus estimates forecast EPS of $0.06 per share, a 500% year-on-year increase, with revenues of $89.42 million, representing a 13.3% rise from the year-ago period.
2. Analyst Price Target Adjustment
Mizuho reduced its price target for Evolus to $15 while maintaining an Outperform rating. The adjustment reflects a revised outlook on the company’s growth trajectory and market positioning within the aesthetic medicine industry.
3. Conference Participation
Evolus will present at the Leerink Partners Global Healthcare Conference, highlighting its strategic initiatives and commercial progress. Management’s presentation is expected to offer insights ahead of the earnings release and inform investor expectations.